Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib

10 Oct 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Lung Cancer Treatments and Mutations
Share to RNA modifications and cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25436805
DOI: 10.1097/jto.0000000000000323

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to CabozantinibPMID 25436805Read ↗

RET-oncogene-targeting drugs draw notice.Semantic proximity Read ↗

Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case SeriesSemantic proximity Read ↗

ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiationSemantic proximity Read ↗

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read ↗

Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.Semantic proximity Read ↗

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenarioSemantic proximity Read ↗

Pralsetinib-Induced Interstitial Pneumonitis in a Patient with Metastatic Pulmonary Spindle Cell Carcinoma Harboring RET fusion: A Case ReportSemantic proximity Read ↗

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.Semantic proximity Read ↗

Remarkable response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: A case reportSemantic proximity Read ↗

Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy.Semantic proximity Read ↗

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.